Kimia Therapeutics
Kimia Therapeutics speeds discovery of novel drug candidates by combining machine learning with automated synthesis and biological screening. Its proprietary ATLAS platform integrates AcTive® Learning, generative chemistry, high-throughput automated synthesis, chemical biology, proteomics, and gene editing to iteratively design and test compounds. Kimia uses automated synthesis and screening pipelines plus ML models to map structure–function relationships and access large target-directed chemical space on demand. The company partners with pharmaceutical and biotechnology firms to de-risk target discovery and optimize lead molecules at scale.
Kimia Therapeutics
Kimia Therapeutics speeds discovery of novel drug candidates by combining machine learning with automated synthesis and biological screening. Its proprietary ATLAS platform integrates AcTive® Learning, generative chemistry, high-throughput automated synthesis, chemical biology, proteomics, and gene editing to iteratively design and test compounds. Kimia uses automated synthesis and screening pipelines plus ML models to map structure–function relationships and access large target-directed chemical space on demand. The company partners with pharmaceutical and biotechnology firms to de-risk target discovery and optimize lead molecules at scale.
TL;DR
Platform: ATLAS platform combines active learning/ML with automated high-throughput synthesis and biological screening to accelerate drug discovery.
Funding: Series A — USD 55,000,000 (announced 2023-12-19).
Founding & HQ: Founded 2023 as a spin‑off of Carmot Therapeutics; headquartered in Berkeley, California.
Leadership: Co‑founders: Stig K. Hansen (CEO/President), Jack Sadowsky (VP, Discovery Chemistry), Ray Fucini (Sr Director, Discovery Platform Technology).
Company Overview
Problem Domain
Drug discovery — mapping relationships between chemical structure and protein function to accelerate target discovery and lead optimization.
Founded
2023
Industry
Biotechnology
Tech Stack
Funding Track Record
USD 55,000,000
Round included participation from Horizons Ventures and individual investors (company disclosure).
Investor Signal
“Series A led by The Column Group and Dimension Capital; participation from Horizons Ventures and individual investor Zachary Hargreaves; board includes representatives from Dimension and The Column Group.”